Publications And Posters All Assays All Instruments All Therapeutic Areas OCTOBER 22, 2021 Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus OCTOBER 22, 2021 Blood Neurofilament Light Chain as a Potential Biomarker for Central and Peripheral Nervous Toxicity in Rats OCTOBER 18, 2021 Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum OCTOBER 15, 2021 Serum neurofilament light chain levels are associated with stroke severity and functional outcome in patients undergoing endovascular therapy for large vessel occlusion OCTOBER 11, 2021 Changes in Blood Biomarkers of Brain Injury and Degeneration Following Long-Duration Spaceflight OCTOBER 11, 2021 Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes OCTOBER 10, 2021 Advances in the analysis of single extracellular vesicles: A critical review OCTOBER 8, 2021 Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome OCTOBER 7, 2021 High Level of Inflammatory Cytokines in the Tears: A Bridge of Patients with Concomitant Exotropia and Dry Eye 1 2 3 4 ... 20 40 ... » 172 Stay Tuned Subscribe to our newsletter SUBMIT info@quanterix.com 617 301 9400 900 middlesex tpke billerica, ma 01821 usa Investor Portal Customer Portal Contact Us Terms And Conditions Privacy Shield Statement © 2021 Quanterix All rights reserved. Privacy Policy By continuing to use this website you are acknowledging and agree with our cookie policy. AGREELearn more

BACK TO WEBINARS Recent Advancements In Neurodegenerative Biomarkers: Progress Towards A Diagnostic Blood Test For Alzheimer’S Disease DATE April 23, 2021 TIME & LOCATION 10:00 am EDT, Virtual With much enthusiasm following the research coming out of AD/PD™2021, we are pleased to bring together leading industry experts to discuss neurological advancements related to the ultra-sensitive quantification of pTau181, pTau217, pTau231, and other neurological biomarkers. This panel discussion and live Q and A will cover the latest developments and opportunities to impact AD clinical trials and diagnostics. The discussion will be led by Quanterix Chairman, Chief Executive Officer, and President, Kevin Hrusovsky and will feature Charlotte Teunissen, Ph.D., UMC Amsterdam, and Henrik Zetterberg. Ph.D., University of Gothenberg. VIEW THE RECORDING Share this page Stay Tuned Subscribe to our newsletter SUBMIT info@quanterix.com 617 301 9400 900 middlesex tpke billerica, ma 01821 usa Investor Portal Customer Portal Contact Us Terms And Conditions Privacy Shield Statement © 2021 Quanterix All rights reserved. Privacy Policy By continuing to use this website you are acknowledging and agree with our cookie policy. AGREELearn more